Altria Group Inc, Reynolds American Inc and Lorillard Inc dismissed
their case after the FDA on May 29 said it would review whether to
mandate advance approval for label alterations such as changes to
logos and background colors, or the use of descriptors such as
"premium tobacco."
In their April lawsuit filed in federal court in Washington, D.C.,
the companies said the 2009 Tobacco Control Act limited FDA
authority to pre-approve label changes to two "narrow"
circumstances: products claiming to lower tobacco-related risks, or
when prior approval is required by regulation.
By expanding its oversight to cover how labels look, the FDA
violated the tobacco companies' commercial speech rights under the
First Amendment, the complaint said.
The plaintiffs included Altria's Philip Morris USA, Reynolds
American's RJ Reynolds and Lorillard Tobacco, whose respective
cigarette brands include Marlboro, Camel and Newport, and some of
their smokeless tobacco units.
In its May 29 statement, the FDA said it would not act against
tobacco companies that do not seek pre-approval for label changes
that create "distinct" products otherwise identical to those being
sold, or where the only change is the quantity in each package.
The FDA said the interim policy would remain in place while the
agency decides whether to adopt new label approval procedures.
[to top of second column] |
Altria spokesman Brian May said there was no need to pursue the
lawsuit in light of the FDA's announcement. Reynolds American
spokesman David Howard declined to comment. Lorillard did not
respond to a request for comment.
FDA spokesman Michael Felberbaum declined to comment.
On May 26, Reynolds American won U.S. antitrust approval to buy
Lorillard, combining the second- and third-largest U.S. cigarette
companies.
The case is Philip Morris USA Inc et al v. FDA et al, U.S. District
Court, District of Columbia, No. 15-00544.
(Additional reporting by Toni Clarke in Washington, D.C.)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|